JP2023532675A5 - - Google Patents

Info

Publication number
JP2023532675A5
JP2023532675A5 JP2022580178A JP2022580178A JP2023532675A5 JP 2023532675 A5 JP2023532675 A5 JP 2023532675A5 JP 2022580178 A JP2022580178 A JP 2022580178A JP 2022580178 A JP2022580178 A JP 2022580178A JP 2023532675 A5 JP2023532675 A5 JP 2023532675A5
Authority
JP
Japan
Prior art keywords
egfr
combination
use according
compound
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022580178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532675A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/067346 external-priority patent/WO2021260109A1/en
Publication of JP2023532675A publication Critical patent/JP2023532675A/ja
Publication of JP2023532675A5 publication Critical patent/JP2023532675A5/ja
Pending legal-status Critical Current

Links

JP2022580178A 2020-06-25 2021-06-24 EGFR突然変異NSCLCの治療に使用するための、CBP/p300ブロモドメイン阻害剤およびEGFR阻害剤の組合せ Pending JP2023532675A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20182364.8 2020-06-25
EP20182364 2020-06-25
EP21167277 2021-04-07
EP21167277.9 2021-04-07
PCT/EP2021/067346 WO2021260109A1 (en) 2020-06-25 2021-06-24 A COMBINATION OF A CBP/p300 BROMODOMAIN INHIBITOR AND AN EGFR INHIBITOR FOR USE IN TREATING EGFR-MUTANT NSCLC

Publications (2)

Publication Number Publication Date
JP2023532675A JP2023532675A (ja) 2023-07-31
JP2023532675A5 true JP2023532675A5 (cg-RX-API-DMAC7.html) 2024-06-19

Family

ID=76502741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580178A Pending JP2023532675A (ja) 2020-06-25 2021-06-24 EGFR突然変異NSCLCの治療に使用するための、CBP/p300ブロモドメイン阻害剤およびEGFR阻害剤の組合せ

Country Status (11)

Country Link
US (1) US20230255966A1 (cg-RX-API-DMAC7.html)
EP (1) EP4171556A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023532675A (cg-RX-API-DMAC7.html)
KR (1) KR20230028512A (cg-RX-API-DMAC7.html)
CN (1) CN115701996B (cg-RX-API-DMAC7.html)
AU (1) AU2021298153A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025911A2 (cg-RX-API-DMAC7.html)
CA (1) CA3183982A1 (cg-RX-API-DMAC7.html)
IL (1) IL299438A (cg-RX-API-DMAC7.html)
MX (1) MX2022016496A (cg-RX-API-DMAC7.html)
WO (1) WO2021260109A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022006394A2 (pt) 2019-10-02 2022-07-26 Tolremo Therapeutics Ag Derivados heterocíclicos, composições farmacêuticas e seu uso no tratamento ou melhora do câncer
WO2021260110A1 (en) 2020-06-25 2021-12-30 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
AU2021298154A1 (en) 2020-06-25 2023-02-23 Tolremo Therapeutics Ag Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer
CA3212085C (en) 2021-04-07 2025-02-11 Tolremo Therapeutics Ag HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR RELIEF OF CANCER
CN120359030A (zh) * 2022-12-15 2025-07-22 冠科美博有限公司 使用c-MET抑制剂治疗对EGFR TKI具有耐药性的癌症
PL449237A1 (pl) * 2024-07-15 2026-01-19 Uniwersytet Łódzki Inhibitor acetylotransferaz do zastosowania w leczeniu niedrobnokomórkowego raka płuc oraz potrójnie negatywnego nowotworu piersi opornego na paklitaksel
WO2026128761A1 (en) 2024-12-11 2026-06-18 Nexo Therapeutics, Inc. Covalent p300 inhibitor compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9005670B2 (en) 2010-01-05 2015-04-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
WO2013148114A1 (en) * 2012-03-30 2013-10-03 University Of Florida Research Foundation, Inc. P300/cbp inhibitors and methods of use
CN105979958A (zh) * 2013-10-11 2016-09-28 基因泰克公司 Cbp/ep300布罗莫结构域抑制剂用于癌症免疫疗法的用途
WO2016123054A2 (en) * 2015-01-26 2016-08-04 The University Of North Carolina At Chapel Hill Kinase drug combinations and methods of use thereof
CN106146508A (zh) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
JP2019524740A (ja) 2016-07-25 2019-09-05 エピザイム インコーポレイテッド Crebbp関連癌の治療法
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
WO2018195450A1 (en) * 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
BR112019025346A2 (pt) * 2017-05-30 2020-06-30 Deciphera Pharmaceuticals, Inc. uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-naftiridin-3-il]-2-fluorofenil]-3-fenilureia e análogos para o tratamento de cânceres associados a anormalidades genéticas no receptor alfa do fator de crescimento derivado de plaquetas
EP3661519A1 (en) * 2017-08-03 2020-06-10 Novartis AG Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
SG11201913249SA (en) * 2017-08-03 2020-02-27 Novartis Ag Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor
GB201806320D0 (en) 2018-04-18 2018-05-30 Cellcentric Ltd Process
IL279734B2 (en) 2018-06-29 2024-11-01 Forma Therapeutics Inc Inhibiting creb binding protein (cbp)
CN110652514A (zh) * 2018-06-29 2020-01-07 上海翰森生物医药科技有限公司 第三代egfr抑制剂的制药用途
US12290521B2 (en) * 2018-07-25 2025-05-06 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating BET inhibitor-resistant cancers

Similar Documents

Publication Publication Date Title
JP2024133475A5 (cg-RX-API-DMAC7.html)
TW202038957A (zh) 抗體-藥物結合物與激酶抑制劑之組合
CN101678029A (zh) 基于嘌呤的cdk抑制剂与酪氨酸激酶抑制剂的组合及其在治疗增生性疾病中的用途
JP2020504742A5 (cg-RX-API-DMAC7.html)
JP2020533298A (ja) Her誘発性薬剤耐性がんの治療又は予防のための化合物、組成物及び方法
JP2025038167A (ja) キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
JP2018090566A5 (cg-RX-API-DMAC7.html)
RU2020108191A (ru) Терапевтическая комбинация ингибитора тирозинкиназы egfr третьего поколения и ингибиторa циклин-d-киназы
RU2014144254A (ru) Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
CN102647986A (zh) 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法
RU2020108192A (ru) Терапевтическая комбинация ингибитора тирозинкиназы egfr третьего поколения и ингибитора raf
CA2439440A1 (en) Treatment of tuberous sclerosis associated neoplasms
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
EP4615869A1 (en) Combination therapy comprising bispecific antibodies comprising an nrp1 binding domain
EP4146217A1 (en) Pharmaceutical combination comprising tno155 and nazartinib
JP2023524789A5 (cg-RX-API-DMAC7.html)
ES2855075T3 (es) Combinación de ceritinib con un inhibidor de EGFR
RU2017143182A (ru) Способы и композиции для ингибирования пути egf/egfr в комбинации с ингибиторами тирозинкиназы
CN113543784A (zh) 用于治疗或预防癌症的喹啉衍生物
RU2015124954A (ru) Фармацевтические комбинации
JP2007537184A (ja) 抗血小板剤に対する耐性を治療するためのジピリダモールの使用
EP3458064A1 (en) Anticancer combination therapy
CA3113408A1 (en) Cancer combination therapy using quinoline carboxamide derivative
JP2024517477A5 (cg-RX-API-DMAC7.html)
KR20260073391A (ko) Wee1 저해제와 pkmyt1 저해제의 조합